<DOC>
	<DOCNO>NCT02352493</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics ALN-CC5 healthy adult volunteer subject PNH</brief_summary>
	<brief_title>A Phase 1/2 Study Investigational Drug , ALN-CC5 , Healthy Adult Volunteers Patients With PNH</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Adequate complete blood count , liver renal function 12lead electrocardiogram ( ECG ) within normal limit Female subject child bear potential agreeing use protocol specify method contraception Male subject agree use protocol specify method contraception Willing provide write informed consent willing comply study requirement Any uncontrolled serious disease , medical surgical condition , may interfere participation clinical study and/or put subject significant risk Received investigational agent within 90 day first dose study drug followup another clinical study History multiple drug allergy intolerance subcutaneous injection Parts A B study : Used prescription medication within 14 day 7 halflives administration first dose study drug . History meningococcal infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>PNH</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>